HMG-CoA reductase inhibitors
- 1 January 2001
- book chapter
- Published by Elsevier in Advances in Protein Chemistry
- Vol. 56, 77-114
- https://doi.org/10.1016/s0065-3233(01)56003-9
Abstract
No abstract availableKeywords
This publication has 158 references indexed in Scilit:
- AtorvastatinDrugs, 1997
- Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A ReappraisalDrug Safety, 1996
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with HypercholesterolemiaThe Journal of Clinical Pharmacology, 1994
- Regulation of the mevalonate pathwayNature, 1990
- Myolysis and Acute Renal Failure in a Heart-Transplant Recipient Receiving LovastatinNew England Journal of Medicine, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Reduction of Serum Cholesterol in Heterozygous Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1983
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981